develop
elisa
sar
synthet
peptid
antigen
solidphas
immunosorb
overlap
peptid
deduc
sarscov
genom
sequenc
synthes
candid
antigen
spike
membran
nucleocapsid
n
protein
candid
immunodomin
n
peptid
select
refin
basi
serolog
reactiv
panel
serum
sampl
patient
clinic
diagnos
sar
nation
taiwan
univers
hospit
taipei
xiaotangshan
sar
emerg
hospit
beij
epitop
map
serolog
valid
describ
develop
peptidebas
elisa
test
hiv
hepat
c
viru
footandmouth
diseas
viru
peptidebas
sar
elisa
well
microtit
plate
coat
mixtur
n
peptid
serolog
reactiv
determin
standard
elisa
procedur
previous
describ
except
detector
horseradish
goat
antihuman
igg
chromaphor
tmb
brief
serum
sampl
includ
two
normal
human
sampl
provid
nonreact
control
dilut
phosphatebuff
salin
carrier
protein
preserv
dilut
serum
sampl
react
peptideco
microtit
well
l
h
plate
wash
time
react
antibodi
conjug
wash
time
react
tmb
reactiv
determin
assay
result
obtain
within
h
result
score
basi
signalcutoff
sc
ratio
cutoff
absorb
determin
mean
two
control
plu
standard
deviat
sd
distribut
normal
human
sampl
figur
seroconvers
panel
collect
serial
serum
sampl
sar
patient
nation
taiwan
univers
hospit
cours
treatment
panel
test
posit
seroconvers
ifa
use
evalu
analyt
sensit
panel
serum
sampl
convalesc
sar
patient
provid
center
diseas
control
depart
health
taiwan
evalu
diagnost
sensit
serum
specimen
confirm
sarscov
infect
clinic
world
health
organ
diagnost
criteria
serolog
whole
elisa
ifa
specimen
also
confirm
rtpcr
sampl
drawn
appropri
time
serolog
reactiv
week
onset
symptom
panel
plasma
sampl
collect
random
blood
donor
florida
obtain
gulf
coast
region
blood
center
houston
tx
specif
evalu
addit
specif
studi
conduct
serum
serolog
reactiv
bloodborn
pathogen
hepat
c
viru
htlv
syphili
obtain
unit
biomed
inc
variou
us
sourc
interfer
panel
suppli
boston
biomedica
inc
boston
serum
sampl
interfer
substanc
commonli
found
process
clinic
sampl
edta
acid
citrat
dextros
citrat
phosphat
dextros
adenin
serum
suppli
nation
taiwan
univers
hospit
patient
associ
typic
atyp
respiratori
pathogen
sarscov
influenza
rubella
cytomegaloviru
epsteinbarr
viru
mycoplasma
pneumonia
serum
sampl
collect
healthi
healthcar
worker
interview
confirm
lack
sign
symptom
sar
includ
fever
respiratori
symptom
diarrhea
peptidebas
elisa
evalu
sensit
seroconvers
eight
seroconvers
panel
obtain
nation
taiwan
univers
hospit
figur
tabl
patient
seroconvers
detect
day
absorb
remain
day
patient
blood
drawn
day
sampl
collect
day
day
seroconvers
appar
day
onset
fever
day
remain
five
six
seroconvers
panel
acut
convalesc
phase
seroposit
observ
day
day
patient
serum
collect
day
figur
peptidebas
elisa
show
analyt
sensit
earliest
time
detect
week
durat
detect
beyond
day
seroreact
patient
also
evalu
standard
ifa
method
comparison
seroconvers
detect
six
patient
ifa
method
within
day
peptid
elisa
data
shown
diagnost
sensit
peptid
elisa
panel
convalescentphas
serum
sampl
sar
patient
provid
refer
panel
center
diseas
control
depart
health
taiwan
sera
confirm
sar
diagnost
serolog
criteria
display
mean
sc
ratio
figur
specif
peptidebas
sar
elisa
test
plasma
obtain
random
florida
blood
donor
gulf
coast
region
blood
center
houston
tx
normal
plasma
sampl
presum
zero
seropreval
rate
gave
mean
sd
subsequ
cutoff
valu
peptidebas
assay
set
mean
duplic
nonreact
control
plu
base
sd
mean
normal
plasma
sampl
distribut
sc
ratio
blood
bank
sampl
plot
figur
mean
sc
ratio
none
show
posit
reactiv
specif
normal
sampl
tabl
peptid
elisa
evalu
specif
collect
serum
sampl
patient
seroposit
bloodborn
pathogen
hiv
hepat
c
viru
htlv
syphili
variou
us
sourc
normal
serum
sampl
spike
interfer
substanc
heparin
edta
acd
boston
biomedica
sampl
seroreact
pathogen
test
neg
peptidebas
sar
elisa
interfer
panel
tabl
peptid
elisa
evalu
specif
serum
sampl
drawn
patient
associ
typic
atyp
respiratori
pathogen
sarscov
nation
taiwan
univers
hospit
includ
sampl
patient
natur
infect
influenza
two
sequenti
bleed
per
influenza
patient
patient
rubella
patient
cytomegaloviru
infect
patient
epsteinbarr
viru
patient
infect
mycoplasma
pneumonia
bacteri
agent
atyp
pneumonia
pre
postvaccin
blood
sampl
patient
given
influenza
vaccin
sampl
test
duplic
sitespecif
antigen
peptid
sarscov
elisa
free
crossreact
respiratori
pathogen
tabl
prospect
studi
perform
determin
asymptomat
infect
among
primari
healthcar
worker
hospit
treat
sar
patient
collect
serum
sampl
healthcar
worker
without
symptom
direct
contact
sar
patient
agre
test
antibodi
sarscov
ho
ping
yang
ming
en
chu
kong
hsin
tai
hospit
approxim
week
outbreak
recogn
ho
ping
yang
ming
hospit
admit
sar
patient
recognit
sar
healthcar
worker
implement
control
measur
subsequ
facil
experienc
transmiss
healthcar
worker
en
chu
kong
hsin
tai
facil
admit
patient
control
measur
implement
neither
hospit
record
transmiss
sar
healthcar
worker
elisa
detect
three
case
sampl
ho
ping
one
case
blood
sampl
nurs
aid
yang
ming
four
posit
sampl
indic
asymptomat
infect
confirm
seroposit
ifa
none
serum
sampl
two
hospit
without
nosocomi
infect
display
seroconvers
conveni
elisa
detect
igg
sarscov
base
sitespecif
synthet
antigen
taken
n
protein
viru
high
specif
crossreact
detect
sampl
associ
common
noncoronaviru
respiratori
pathogen
addit
lack
detect
reactiv
among
us
blood
donor
support
specif
assay
distinguish
sarscov
infect
infect
human
coronavirus
presenc
anticoronaviru
antibodi
among
us
popul
size
strongli
anticip
incid
high
respiratori
infect
observ
even
among
healthi
young
adult
new
peptidebas
elisa
equival
sensit
immunoassay
sar
detect
day
synthet
antigen
provid
advantag
high
standard
freedom
biohazard
eas
scaleup
product
moreov
test
elisa
format
readili
autom
largescal
screen
highli
specif
peptidebas
sar
antibodi
test
conveni
mean
carri
widespread
retrospect
surveil
propos
china
trace
hotspot
person
carri
antibodi
sarscov
track
origin
diseas
preliminari
survey
peptid
elisa
detect
asymptomat
cluster
seroconvers
among
expos
healthcar
worker
two
taiwan
hospit
also
nosocomi
diseas
contrast
seroconvers
found
among
expos
healthcar
worker
two
hospit
appar
diseas
transmiss
healthcar
worker
find
asymptomat
seroposit
person
indic
test
use
larger
retrospect
surveil
studi
need
fulli
defin
epidemiolog
spectrum
diseas
